Dr. Fu is the co-founder and current CEO of Green Therapeutics, a premier cannabis cultivation and manufacturing company operating in Nevada since 2015. Prior to that Dr. Fu was the President of MedMen from 2014-2015. Dr. Fu holds a Doctor of Pharmacy and MBA from the University of New Mexico and is a Board-Certified Nuclear Pharmacists in the state of Nevada. Dr. Fu is the former Manager and Equity Partner of Biotech Pharmacy. As a start-up, Biotech Pharmacy grew to become the largest independent nuclear pharmacy chain in the Southwest of the United States. In 2009, Biotech Pharmacy exited to healthcare giant Cardinal Health (ranked 19th on the Fortune 500 list). Dr. Fu is active in the Las Vegas community having been involved with several local charitable organizations, such as the Crohn’s and Colitis Foundation of America from 2007 to present, and the Alzheimer’s Association from 2004 to present.
Mr. Geller has extensive experience in the small and microcap markets and has worked on a variety of debt, equity and hybrid deals across multiple industries. Since 2017 Mr. Geller has been the Chief Investment Officer of Leonite Capital LLC, a diversified family office investment vehicle with extensive holdings in real estate, venture capital, private equity, public equities (with a focus on small-cap and micro-cap public companies), alternative lending, and hedge funds. Since October 30, 2018, Mr. Geller has been the Interim Chief Executive Officer of Parkit Enterprise Inc. (TSXV: PKT), a company engaged in the acquisition, optimization and asset management of income producing parking facilities across North America. Mr. Geller is also a Non-Executive Director of Nova Minerals Ltd. (ASX: NVA), a mining company based in Australia focused on gold exploration and a member of the board of directors of DealFlow Financial Products Inc., an information services provider to investment banks, investment funds and financial services companies.
Mr. Esteireiro is a Principal and the Head of Equities at Eight Capital (formerly Dundee Securities Inc.). Mr Esteireiro has over two decades of capital markets experience at some of Canada’s premier full-service investment firms. His previous roles include Managing Director and Head of Canadian Institutional Equity Trading at Canaccord Genuity, Founding Partner and Head of Equity Trading at Genuity Capital Markets, a firm he helped build into one of Canada’s leading independent brokerage firms, and Managing Director and Head of Institutional Equity Trading at CIBC World Markets. John brings a wealth of experience advising on M&A and capital raising within the cannabis space having led numerous financings for U.S. cannabis companies.
Dr. Dyck is a distinguished research scientist in the Department of Pediatrics at the University of Alberta and currently directs the University of Alberta Cardiovascular Research Centre and co-directs the pan-Alberta program known as Alberta HEART. Dr. Dyck is the former Research and Science team lead at Aurora Cannabis Inc. (TSX: ACB). Dr. Dyck is the Canada Research Chair in Molecular Medicine, having published over 230 peer-reviewed research papers in this area. Dr. Dyck has extensive experience in the field of drug discovery and commercialization, is co-founder of a successful University of Alberta spin-off company, currently holds more than 100 patents and has numerous collaborations with large pharmaceutical companies. Dr. Dyck serves on the board of Nutritional High International Inc. (CSE: EAT), a U.S. multi-state cannabis company engaged in the manufacturing, branding and distribution of cannabis consumer products. Dr. Dyck also serves on the board of CTT Pharmaceutical Holdings, Inc., and is the co-chairman of the National Research Council at Diabetes Canada. Dr. Dyck received a PhD in Medical Sciences from the University of Alberta in 1995 and trained at Dartmouth Medical School (Hanover, New Hampshire) and Baylor College of Medicine (Houston, Texas).
Mr. Kapadia has been the managing Partner at Kapadia & Associates, a high net-worth accounting and advisory firm since 2003 and is a former accountant with PriceWaterhouseCoopers from 1998 to 2002. Mr. Kapadia is an experienced entrepreneur, with over 23 years of experience advising on regulatory, tax and finance matters in public, private, and non-profit enterprises. Mr. Kapadia serves as the Chair of Finance and Governance at Ontario Cannabis Retail Corporation, Chair of the By-law review committee and has also previously served as interim Chairman of the Board of Directors at Ontario Cannabis Retail Corporation. Mr. Kapadia serves on the board at AI – LP, a firm focused on early stage technology startups, is currently the Chair of the advisory board at Huex Labs, a leading artificial intelligence company and is a former member of the board at Optimal Research Corporation, a medical research company. Mr. Kapadia holds a Bachelor of Arts from the University of Waterloo and a Masters of Accounting from the University of Waterloo.